BRAF mutations in non-Hodgkin's lymphoma by Lee, J W et al.
Short Communication
BRAF mutations in non-Hodgkin’s lymphoma
JW Lee
1, NJ Yoo
1, YH Soung
1, HS Kim
1, WS Park
1, SY Kim
1, JH Lee
1, JY Park
1, YG Cho
1, CJ Kim
1,Y HK o
2,
SH Kim
1, SW Nam
1, JY Lee
1 and SH Lee*,1
1Department of Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul 137-701, Korea;
2Department of
Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul 135-710, Korea
Ras proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.
BRAF, which encodes an RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human
cancers. The activating mutation of BRAF is known to play a role in tumour development. As there have been no data on the BRAF
mutation in non-Hodgkin’s lymphoma (NHL), we analysed the genomic DNAs from 164 NHLs by polymerase chain reaction (PCR)-
based single-strand conformation polymorphism (SSCP) for the detection of somatic mutations of BRAF (exons 11 and 15). Overall,
we detected BRAF mutations in four NHLs (2.4%). Whereas most BRAF mutations in human cancers involved V599 of BRAF, all of
the four BRAF mutations in the NHLs involved other amino acids (one G468A, two G468R and one D593G). To our knowledge, this
is the first report on BRAF mutation in NHL, and the data indicate that BRAF is occasionally mutated in NHL, and suggest that BRAF
mutation may contribute to the tumour development in some NHLs.
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The activated RAS proteins excite the mitogen-activated protein
(MAP) kinase pathway (RAS–RAF–MEK–ERK–MAP kinase
pathway) by recruiting the cytosolic protein RAF (Downward,
2003). RAF gene family consists of three members (ARAF1, BRAF
and RAF1), each encoding serine/threonine kinases that are
regulated by binding to RAS. RAS–RAF–MEK–ERK–MAP kinase
pathway plays a critical role in cell proliferation, and is frequently
activated in cancer cells. For example, approximately 10–20% of
all human tumours contain mutated versions of RAS proteins (Bos,
1989). Recently, Davies et al (2002) identified somatic mutations of
BRAF in 66% of malignant melanomas and at a lower frequency in
a wide range of human cancers. So far, all BRAF mutations have
been reported within two kinase domains (G-loop and activation
segment domains), and the most common mutation is a single
substitution, V599E (Brose et al, 2002; Davies et al, 2002; Naoki
et al, 2002; Rajagopalan et al, 2002; Yuen et al, 2002; Pollock et al,
2003; Satyamoorthy et al, 2003). Mutated BRAF proteins have
elevated kinase activity and transforming activity in NIH3T3 cells
(Davies et al, 2002). Furthermore, RAS function is not required for
the growth of cancer cell lines with the V599E mutation (Davies
et al, 2002). Several studies have reported a low incidence of Ras
gene mutation in non-Hodgkin’s lymphoma (NHL) (Ahuja et al,
1990). Although screening of BRAF mutation in human tumours
has widely been performed, to date the data on BRAF mutation in
NHL tissues is lacking. In the present study, we investigated the
occurrence of BRAF gene mutations in NHLs.
MATERIALS AND METHODS
Paraffin-embedded tissues of human NHL were obtained from 164
patients. These samples were stained with haematoxylin–eosin,
examined by immunohistology, and then classified according to
the Revised European-American Lymphoma (REAL) classification
(Harris et al, 1994). The NHLs analysed consisted of seven B-cell
small lymphocytic lymphomas, three mantle cell lymphomas, four
follicular lymphomas, 49 mucosa-associated lymphoid tissue
(MALT)-type lymphomas, 67 diffuse large B-cell lymphomas, four
precursor T-lymphoblastic lymphomas, one T-cell chronic lym-
phocytic leukaemia, 14 peripheral T-cell lymphomas, unclassified,
14 angiocentric lymphomas, and one intestinal T-cell lymphoma.
Ethical committee approval for the study was obtained. Through
the microdissection technique, we selectively procured tumour
cells and corresponding normal cells from histological sections of
the 164 NHLs. Briefly, malignant cells were selectively procured
from haematoxylin and eosin-stained sections using a 30G1/2
hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA)
affixed to a micromanipulator, as described previously (Lee et al,
1998). We also microdissected normal cells and used them for
corresponding normal DNA. This microdissection technique used
in this study has been proved to be precise and effective for
procurement of tumour cells without normal cell contamination
(Lee et al, 1998). DNA extraction was performed by a modified
single-step DNA extraction method, as described previously (Lee
et al, 1998).
Genomic DNA each from normal cells or tumour cells was
amplified with two primer pairs covering exons 11 and 15 of BRAF
gene, because all of the BRAF mutations have been so far detected
in exons 11 and 15 that encode the kinase domains in G-loop and
the activation segment of BRAF, respectively. Radioisotope was
incorporated into the PCR products for detection by autoradio-
gram. The PCR reaction mixture was denatured for 1min at 941C
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sand incubated for 30 cycles. Other procedures of polymerase chain
reaction (PCR) and single-strand conformation polymorphism
(SSCP) analysis were performed as described previously (Shin et al,
1999). After SSCP, DNAs showing mobility shifts were cutout from
the dried gel, and reamplified for 30 cycles using the same primer
sets. Sequencing of the PCR products was carried out using the
cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA)
according to the manufacturer’s recommendation.
RESULTS
SSCP analysis of BRAF identified four aberrant bands (Figure 1).
Enrichment and DNA sequence analysis of these aberrantly
migrating bands led to the identification of four BRAF mutations
(2.4%) (Figure 1). All of the four BRAF mutations were observed in
diffuse large B-cell lymphomas (6.0% of the 67 cases). Although
BRAF mutations were detected only in diffuse large B-cell
lymphomas, this relationship was not statistically significant
(P40.05). Three of the four BRAF mutations involved codon 468
(two G468R and one G468A) in the G-loop domain, and the
remaining one was found at codon 593 (D593G) in the activation
segment domain (Table 1, Figure 1). None of the corresponding
normal samples showed evidence of mutations by SSCP (Figure 1),
indicating the mutations detected in the specimens had risen
somatically. We repeated the experiments two times, including
tissue microdissection, PCR, SSCP and sequencing analysis to
ensure the specificity of the results, and found that the data were
consistent (data not shown).
DISCUSSION
Whereas the malignant melanoma is the most common tumour
with BRAF mutations (roughly 60%), this tumour is known to
possess a much lesser frequency of RAS mutations. Such
differential occurrences of BRAF and RAS mutation in some
human cancers led us to analyse BRAF mutation in NHL in which
RAS mutation is known to be an uncommon event. We found that
BRAF gene is somatically mutated in NHLs, indicating that RAS–
RAF kinase pathway in some NHLs may be regulated by somatic
mutations of BRAF. Despite the low frequency of BRAF mutation
in NHL compared with that of malignant melanoma, our data
suggest that alteration of RAS–RAF kinase pathway by BRAF
mutation may play an important role in NHL carcinogenesis.
In the present study, none of the BRAF mutations involved the
amino acid V599. The data are quite contrast to those of malignant
melanomas, where approximately 90% of BRAF mutations
involved V599, raising the possibility that the contribution of
BRAF mutations in the development of NHL might be different
from that of malignant melanoma. Additionally, three (two G468A
and one G468R) of the four BRAF mutations in this study involved
the same amino acid (G468) that is located in the GXGXXG motif
within the G-loop of the kinase domain. The G468A mutation was
proven to be an activating mutation by the kinase assay and the
transformation assay (Davies et al, 2002). For G468R, a novel
BRAF mutation, its functional implication is not known at this
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Figure 1 BRAF gene mutations in NHLs. SSCP (A–C) and DNA
sequencing analyses (D–F) of DNA from tumours (lane T) and normal
tissues (lane N). Exon 11 (A, B) and exon 15 (C)o fBRAF were amplified.
SSCPs of DNA from the tumours show wild-type bands and additional
aberrant bands (arrows) as compared to SSCP from normal cells from the
same patients. (D) Sequencing analysis from the aberrant band in (A).
There is a G to C transversion at nucleotide 1403 of BRAF (arrow) in
tumour tissue as compared to normal tissue. (E) Sequencing analysis from
the aberrant band in (B). There is a G to C transversion at nucleotide 1402
of BRAF (arrow) in tumour tissue as compared to normal tissue. (F)
Sequencing analysis from the aberrant band in (C). There is an A to G
transition at nucleotide 1778 of BRAF (arrow) in tumour tissue as
compared to normal tissue. Numbering of cDNA of BRAF was made in
respect to the ATG start codon (GenBank).
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sstage. In one NHL, we also found D593G BRAF mutation that has
also been detected in colon tumours previously.
The most impressive examples of recent cancer therapies used
protein kinase inhibitors such as Imanitib (Gleevec) (Downward,
2003). Since RAS–RAF–MEK–ERK–MAP kinase pathway is
activated by protein kinase, therapies that target this signalling
pathway would therefore be very valuable in treating tumours that
have activating mutations of BRAF. In this respect, the present
study may provide the possibility of therapy targeting mutated
BRAF in NHL.
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Table 1 Summary of BRAF mutations identified in the NHLs
BRAF mutations
Nucleotide
Amino
acids Anatomical site Histologic type
G1403C G468A Cervical lymph node Diffuse large B-cell lymphoma
G1403C G468A Cervical lymph node Diffuse large B-cell lymphoma
G1402C G468R Tongue mucosa Diffuse large B-cell lymphoma
A1778G D593G Ileum Diffuse large B-cell lymphoma
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